Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world,
especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2 …

New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …

Background Bortezomib-based induction followed by high-dose melphalan (200 mg/m 2)
and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with …

Multiple myeloma is a treatable, but currently incurable, hematological malignancy of
plasma cells characterized by diverse and complex tumor genetics for which precision …

Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need
of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene …

Background Lenalidomide plus dexamethasone is a reference treatment for patients with
newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with …

The introduction of novel agents has led to major improvements in clinical outcomes for
patients with multiple myeloma. To shorten evaluation times for new treatments, health …

Multiple myeloma (MM) accounts for 1% of all cancers and $10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …